Dear Editor,

We have read with great interest the recent published manuscript by Caiazza et al. (2016), which provides novel exciting findings about the potential therapeutic value of enzalutamide in patients with androgen receptor (AR)-positive triple-negative breast cancer (TNBC). Some previous studies have shown promising antitumor effects of this drug in breast tumors. Thus, enzalutamide-mediated AR inhibition has been reported to reduce proliferation, anchorage-independent growth, migration and invasion and increases apoptosis of TNBC cells in vitro and decrease the viability of TNBC xenografts in vivo (Cochrane et al. 2014, Barton et al. 2015). In concordance with these data, Caiazza and coworkers found that enzalutamide reduced cell …